CEACAM5 and metastatic colorectal cancer: A clinical trial of the Ad5 [E1-, E2b-]-CEA (ETBX-011) vaccine in patients with metastatic colorectal cancer demonstrated the ability to administer multiple vaccinations to immunocompromised patients safely, and provided a favorable survival profile [1, 10].